This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Subscribe To Our Newsletter & Stay Updated
